peptide mapping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-17 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
== Universities == According to the 2020 QS World University Rankings, Chulalongkorn University (CU) was ranked 247th in the world and earned the top ranking in Thailand for the seventh consecutive year. Also ranked were Mahidol University (314th), and Chiang Mai University and Thammasat University (both in the 601–650 tranche), and four other Thai universities in the 801–1,000 tranche. The Times Higher Education Asia University Rankings 2018 ranked Mahidol University as the top Thai institution. It ranked 97 of some 350 universities (1=best; 350=lowest). King Mongkut's University of Technology Thonburi was ranked 116, Chulalongkorn University 164, and Suranaree University of Technology 168. Thailand had no other universities in the top 200. Chulalongkorn University was ranked number one in Thailand and 45th in Asia in 2016. Mahidol University was ranked the top Thai university among the top 200 Asian (including Middle Eastern) universities in 2016 by Times Higher Education Asia University Rankings 2016.
Upflow columns where input water enters from the bottom and regenerants enter from the top of the ion exchange column. Upflow regeneration where water enters from the top and regenerants enter from the bottom. In both cases, separate distribution headers (input water, input regenerant, exit water, and exit regenerant) must be tuned to: the input water quality and flow, the time of operation between regenerations, and the desired product water analysis. Counter-current deionization is the more attractive method of ion exchange. Chemicals (regenerants) flow in the opposite direction to the service flow. Less time for regeneration is required when compared to cocurrent columns. The quality of the finished product can be as low as .5 parts per million. The main advantage of counter-current deionization is the low operating cost, due to the low usage of regenerants during the regeneration process.
where I(iM)is the count rate of the isotope iM of element M. The counting rate of the isotope is dependent on the concentration, XM and the element's isotopic abundance, denoted Ai. Because the primary ion beam determines the secondary ions, Y, that are sputtered, the density of the primary ion beam, db, which is defined as the amount of ions per second per unit of surface area, will affect a portion of the surface area of the sample, S, with an even distribution of the primary ions. Of the sputtered secondary ions, there is only a fraction that will be ionized, Yi. The probability that any ion will be successfully transferred from mass spectrometer to detector is T. The product of Yi and T determines the amount of isotopes that will be ionized, as well as detected, so it is considered the useful yield.
A nitrovasodilator is a pharmaceutical agent that causes vasodilation (widening of blood vessels) by donation of nitric oxide (NO), and is mostly used for the treatment and prevention of angina pectoris. This group of drugs includes nitrates (esters of nitric acid), which are reduced to NO in the body, as well as some other substances.
Sources: en.wikipedia.org
=== Non-plaque-induced === These are far less common than plaque-induced gingival lesions. Non-plaque-induced gingival disease is an inflammation of the gingiva that does not result from dental plaque, but from other gingival diseases caused by bacterial, viral, fungal, or genetic sources. Although this gingival disease is less common than those which are plaque-induced, it can have a serious impact on the patient's overall health. Inflammation can also be caused by allergic reactions to materials used in dental restorations, specific toothpastes, mouthwashes, and even some foods. Trauma, reactions to foreign bodies, or toxic reactions can also contribute to this non-plaque-induced gingivitis. Furthermore, genetics can play a significant role. Specifically, hereditary gingival fibromatosis is known to cause non-plaque-induced gingival lesions. However, sometimes, there is no specific cause for this form of gingival disease.
When walking at a leisurely pace on level ground (no incline), but there is loose gravel or sand, long grass, snow, mud, or walking into a headwind, that added resistance (requiring more effort) makes the activity more reliant on muscle glycogen also. These and other surfaces, such as ice, can make you tense your muscles (which is anearobic requiring muscle glycogen) as you protect yourself from slipping or falling. Those with muscle glycogenoses can maintain a healthy life of exercise by learning activity adaptations, utilizing the bioenergetic systems that are available to them. Depending on the type of activity and whether they are in second wind, they slow their pace or rest briefly when need be, to make sure not to empty their "ATP reservoir."
Members of parliament refers to the elected members of the Riksdag. In Swedish, an MP is usually referred to as a riksdagsledamot (member of the Riksdag) or a riksdagsman (gentleman of the Riksdag). The former is in more common use today, especially in official contexts, due to its status as a unisex word, while the latter was used more often historically and literally refers to a male MP exclusively. The parliament is a unicameral assembly with 349 members who are chosen every four years in general elections. To become an MP, a person must be entitled to vote (i.e. be a Swedish citizen, be at least 18 years old and be or have been resident in Sweden) and must be nominated by a political party. The MPs are elected by proportionality in constituencies across the nation. To decide which candidate will be elected the modified Sainte-Laguë method is used. This method usually but not always gives an accurate result in proportion to cast votes. The salaries of the MPs are decided by the Riksdag Pay Committee (Riksdagens arvodesnämnd), a government agency under the Riksdag. Since 1 November 2007, the basic monthly pay of an MP is SEK52,900 (ca. US$6,500). The pay of the speaker is SEK126,000 a month (ca. US$15,000), which is the same as that of the prime minister. The deputy speakers receive an increment of 30% of the pay of a member. The chairs and deputy chairs of the parliamentary committees receive a similar increment of 20% and 15% respectively.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.